Please login to the form below

Not currently logged in

ACPs to lead gene therapies in haemophilia market growth


New therapies to hit existing players

Amgen gets block on sales of Repatha rival in Germany

Amgen flagPart of ongoing battle with Sanofi and Regeneron

Reckitt hammered by $1.4bn opioid settlement bill

Reckitt BenckiserCase centres on Subaxone marketing practices

Alnylam gains key NICE approval for Onpattro

OnpattroImportant milestone for company's first product

BioNTech raises €290m for mRNA cancer vaccine platform

BioNTechFunds will help lead melanoma candidate progress

Agencies big and small celebrate Communiqué wins

Sandemann and DunnNo fewer than 15 agencies won top honours

Evotec spins off cancer tech into new Breakpoint company

Breakpoint TherapeuticsWill challenge AstraZeneca and others in DNA damage response

Paul Morrissey joins OPEN Health

Open HealthWill liaise with client procurement and lead expansion

M&F Health, 90TEN and Sanofi among big winners at Communiqué Awards

Communique19Full results from health comms awards

Q&A with Tim Cockroft

PME interviews the founding director of akt health communications

Featured jobs

Subscribe to our email news alerts


Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...